Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ‐12420), a novel potassium‐competitive acid blocker, in healthy male subjects

• Published in: Alimentary pharmacology & therapeutics Vol. 50; no. 7; pp. 751 - 759
• Main Authors: Han, Sungpil, Choi, Hee Youn, Kim, Yo Han, Nam, Ji Yeon, Kim, Bongtae, Song, Geun Seog, Lim, Hyeong‐Seok, Bae, Kyun‐Seop
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.10.2019
• Subjects: Acids; Administration, Oral; Adult; Benzene Derivatives - administration & dosage; Clinical trials; Complications; Dosage; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole - administration & dosage; Esophagus; Gastric Acid - metabolism; Gastric juice; Gastroesophageal reflux; H(+)-K(+)-Exchanging ATPase - metabolism; Health risk assessment; Helicobacter pylori; Humans; Imidazoles - administration & dosage; Male; Middle Aged; Omeprazole; Pharmacodynamics; Pharmacokinetics; Potassium; Safety; Urine; Young Adult

Summary Background Tegoprazan (CJ‐12420) is a potassium‐competitive acid blocker (P‐CAB) with therapeutic potential for gastro‐oesophageal reflux disease (GERD) by reversibly suppressing gastric H+/K+‐ATPase. Aims To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of tego...